Clinical Trial Update: Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating radiolabeled Gallium-68 PSMA PET/CT imaging for detecting prostate cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-01-05